Mats O. Karlsson

Prof. Mats O. Karlsson

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MKMats O. Karlsson
Mats O. Karlsson
RSR M Savic
R M Savic

1 March 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MKMats O. Karlsson
Mats O. Karlsson
ILIrja Lutsar
Irja Lutsar
PMPeter A. Milligan
Peter A. Milligan
Voriconazole is a potent triazole with broad-spectrum antifungal activity against clinically significant and emerging pathogens. The present population pharmacokinetic analysis evaluated voriconazole plasma concentration-time data from three studies of pediatric patients of 2 to <12 years of age, incorporating a range of single or multiple intravenous (i.v.) and/or oral (p.o.) doses. An appropriate pharmacokinetic model for this patient population was created using the nonlinear mixed-effect modeling approach. The final model described voriconazole elimination by a Michaelis-Menten process and distribution by a two-compartment model. It also incorporated a statistically significant ( P < 0.001) influence of the CYP2C19 genotype and of the alanine aminotransferase level on clearance. The model was used in a number of deterministic simulations (based on various fixed, mg/kg of body weight, and individually adjusted doses) aimed at finding suitable i.v. and p.o. voriconazole dosing regimens for pediatric patients. As a result, 7 mg/kg twice a day (BID) i.v. or 200 mg BID p.o., irrespective of body weight, was recommended for this patient population. At these doses, the pediatric area-under-the-curve (AUC) distribution exhibited the least overall difference from the adult AUC distribution (at dose levels used in clinical practice). Loading doses or individual dosage adjustments according to baseline covariates are not considered necessary in administering voriconazole to children.

8 September 2017 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
ADAnne-Gaëlle Dosne
Anne-Gaëlle Dosne
MBMartin Bergstrand
Martin Bergstrand
MKMats O. Karlsson
Mats O. Karlsson
Quantifying the uncertainty around endpoints used for decision-making in drug development is essential. In nonlinear mixed-effects models (NLMEM) analysis, this uncertainty is derived from the uncertainty around model parameters. Different methods to assess parameter uncertainty exist, but scrutiny towards their adequacy is low. In a previous publication, sampling importance resampling (SIR) was proposed as a fast and assumption-light method for the estimation of parameter uncertainty. A non-iterative implementation of SIR proved adequate for a set of simple NLMEM, but the choice of SIR settings remained an issue. This issue was alleviated in the present work through the development of an automated, iterative SIR procedure. The new procedure was tested on 25 real data examples covering a wide range of pharmacokinetic and pharmacodynamic NLMEM featuring continuous and categorical endpoints, with up to 39 estimated parameters and varying data richness. SIR led to appropriate results after 3 iterations on average. SIR was also compared with the covariance matrix, bootstrap and stochastic simulations and estimations (SSE). SIR was about 10 times faster than the bootstrap. SIR led to relative standard errors similar to the covariance matrix and SSE. SIR parameter 95% confidence intervals also displayed similar asymmetry to SSE. In conclusion, the automated SIR procedure was successfully applied over a large variety of cases, and its user-friendly implementation in the PsN program enables an efficient estimation of parameter uncertainty in NLMEM.

11 September 2002 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RXRujia Xie
Rujia Xie
RMRon H. J. Mathijssen
Ron H. J. Mathijssen
ASAlex Sparreboom
Alex Sparreboom
JVJaap Verweij
Jaap Verweij
MKMats O. Karlsson
Mats O. Karlsson
Objectives Our objective was to build population pharmacokinetic models that describe plasma concentrations of irinotecan (CPT‐11) and its metabolites 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) and SN‐38 glucuronide (SN‐38G) and to investigate the pharmacokinetic‐pharmacodynamic relationships between drug exposure and diarrhea, the major dose‐limiting toxicity. Methods Data were obtained from 109 patients (65 men and 44 women) who received 1.5‐hour (range, 0.75‐ to 2.25‐hour) intravenous infusions of irinotecan at doses that ranged from 100 to 350 mg/m2; 44 patients had a second course. The population pharmacokinetic models were developed to describe plasma concentration‐time profiles. The area under the concentration‐time curve from time zero to 60 hours [AUC (0–60)] was used as a measure of drug exposure to model the probabilities of diarrhea with use of a logistic regression model. Results A 3‐compartment pharmacokinetic model best described the disposition of irinotecan, whereas SN‐38 and SN‐38G showed 2‐compartmental characteristics. The population estimate of clearance for irinotecan was 31.6 L/h, and the volume of distribution at steady‐state (VSS) was 263 L. The clearance divided by formation fraction (Fm) was 712 L/h and 66.8 L/h for SN‐38 and SN‐38G, respectively. The VSS/Fm was 72,000 L for SN‐38 and 85.4 L for SN‐38G. The frequencies of diarrhea scores in this study were 46% (grade 0), 28% (grade 1), 20% (grade 2), 4% (grade 3), and 2% (grade 4). Significant correlations between AUC(0–60) and diarrhea scores were found for irinotecan (P < .05) and SN‐38G (P < .01) but not for SN‐38 or the biliary index. Conclusions In this population analysis, irinotecan and SN‐38G AUC values were appropriate predictors of the risk for diarrhea, and SN‐38G AUC showed the stronger relationship of the two. The developed population models may be useful in further clinical development of this agent. Clinical Pharmacology & Therapeutics (2002) 72, 265–275; doi: 10.1067/mcp.2002.126741

15 August 2003
Verified
Journal Article
Closed access
RMRon Mathijssen
Ron Mathijssen
SMSharon Marsh
Sharon Marsh
MKMats O. Karlsson
Mats O. Karlsson
RXRujia Xie
Rujia Xie
SBSharyn D. Baker
Sharyn D. Baker
HMHoward L McLeod
Howard L McLeod

2 April 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
KSKinjal Sanghavi
Kinjal Sanghavi
JRJakob Ribbing
Jakob Ribbing
JRJames A. Rogers
James A. Rogers
MAMariam A. Ahmed
Mariam A. Ahmed
MKMats O. Karlsson
Mats O. Karlsson
FCfor the ISoP Standards & Best Practices Committee
for the ISoP Standards & Best Practices Committee
Modeling the relationships between covariates and pharmacometric model parameters is a central feature of pharmacometric analyses. The information obtained from covariate modeling may be used for dose selection, dose individualization, or the planning of clinical studies in different population subgroups. The pharmacometric literature has amassed a diverse, complex, and evolving collection of methodologies and interpretive guidance related to covariate modeling. With the number and complexity of technologies increasing, a need for an overview of the state of the art has emerged. In this article the International Society of Pharmacometrics (ISoP) Standards and Best Practices Committee presents perspectives on best practices for planning, executing, reporting, and interpreting covariate analyses to guide pharmacometrics decision making in academic, industry, and regulatory settings.